In one paragraphArticle in Disease models & mechanisms, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from itWhat it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
11 authors.
Jack BarringtonDivision of Neuroscience, School of Biological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester Academic Health Science Centre, AV Hill Building, Manchester M13 9PT, UK.ORCID 0000-0002-4554-6037 Jack Rivers-AutyDivision of Neuroscience, School of Biological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester Academic Health Science Centre, AV Hill Building, Manchester M13 9PT, UK.ORCID 0000-0001-5321-2347 Patrick StrangwardDivision of Neuroscience, School of Biological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester Academic Health Science Centre, AV Hill Building, Manchester M13 9PT, UK.ORCID 0000-0001-5952-2864 Sabrina TamburranoDivision of Neuroscience, School of Biological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester Academic Health Science Centre, AV Hill Building, Manchester M13 9PT, UK.ORCID 0000-0003-3454-149X Nikolett Lénárt"Momentum" Laboratory of Neuroimmunology, HUN-REN Institute of Experimental Medicine, Szigony u. 43, Budapest 1083, Hungary.ORCID 0000-0002-7456-949X Tessa SwantonDivision of Neuroscience, School of Biological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester Academic Health Science Centre, AV Hill Building, Manchester M13 9PT, UK.ORCID 0000-0003-1776-080X Eloise LemarchandDivision of Neuroscience, School of Biological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester Academic Health Science Centre, AV Hill Building, Manchester M13 9PT, UK.ORCID 0000-0001-6781-0444 Adrian R Parry-JonesGeoffrey Jefferson Brain Research Centre, Manchester Academic Health Science Centre, Northern Care Alliance NHS Foundation Trust, The University of Manchester, Manchester M13 9PT, UK.ORCID 0000-0002-4462-3846 Ádám Dénes"Momentum" Laboratory of Neuroimmunology, HUN-REN Institute of Experimental Medicine, Szigony u. 43, Budapest 1083, Hungary.ORCID 0000-0001-6919-4905 David BroughDivision of Neuroscience, School of Biological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester Academic Health Science Centre, AV Hill Building, Manchester M13 9PT, UK.ORCID 0000-0002-2250-2381 Stuart M AllanDivision of Neuroscience, School of Biological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester Academic Health Science Centre, AV Hill Building, Manchester M13 9PT, UK.ORCID 0000-0001-9646-4456 Funding
Hungarian Academy of Sciences Momentum ProgramMagyar Tudományos AkadémiaMedical Research Council DTP PhD studentshipMedical Research Council MR/T016515/1Natalie Kate Moss TrustUniversity of Manchester
6 · The paper itselfAbstract
Intracerebral haemorrhage (ICH) is a devastating stroke subtype lacking effective therapies. Understanding key pathological processes related to acute brain damage will help deliver better outcomes for ICH. Herein, we provide evidence that myeloid cell trafficking to the parenchyma is a conserved feature of ICH in clinical and experimental settings. Consistent with others, we show that monocytes contribute to acute brain damage following collagenase-induced murine ICH. Using RNA sequencing, we identified the pro-inflammatory cytokine interleukin-1 (IL-1) as a potential upstream regulator of the acute inflammatory response, with histological data pinpointing mononuclear phagocytes as the principal cellular source of IL-1 in patient and animal tissue. In agreement, inhibition of IL-1 receptor 1 (IL-1R1) with IL-1 receptor antagonist reduced recruitment of myeloid cells. However, IL-1R1 inhibition also worsened neuromotor outcomes and reduced cerebral blood flow to the affected hemisphere. Thus, we reveal dichotomous actions of IL-1-dependent inflammation following brain haemorrhage. Although IL-1 regulates myeloid cell trafficking, it also appears to regulate cerebral blood flow. Therefore, further investigation into the consequences of IL-1 signalling following brain haemorrhage is required to clarify future therapeutic options.
Indexed as
Cell MovementCerebral HemorrhageCerebrovascular CirculationInterleukin-1Myeloid CellsAnimalsHumansInflammationMaleMiceMice, Inbred C57BLMonocytesReceptors, Interleukin-1 Type ISignal TransductionInterleukin-1Receptors, Interleukin-1 Type IBrain inflammationInterleukin-1Intracerebral haemorrhageNeuroinflammationStroke
Identifiers
PMID40836597
PMCPMC12519545
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390